Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced Solid Cancer × Injections × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 61 Breast Neoplasms 47 Myelodysplastic Syndromes 25 Neoplasms 23 Advanced Solid Tumor 23 Carcinoma, Non-Small-Cell Lung 21 Advanced Solid Tumors 21 Prostatic Neoplasms 20 Stomach Neoplasms 18 Recurrence 17 Multiple Myeloma 16 Carcinoma, Hepatocellular 16 Neoplasm Metastasis 15 Leukemia, Myelomonocytic, Chronic 13 Solid Tumor 12 Pancreatic Neoplasms 12 Ovarian Neoplasms 12 Lung Neoplasms 12 Uterine Cervical Neoplasms 10 Melanoma 10 Lymphoma, Large B-Cell, Diffuse 10 Sarcoma 9 Triple Negative Breast Neoplasms 8 Small Cell Lung Carcinoma 8 Myeloproliferative Disorders 8 Colorectal Neoplasms 8 Lymphoma, B-Cell 7 Esophageal Neoplasms 7 Biliary Tract Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6

Interventions

pembrolizumab 1 SH-1028 1 Injections 1 2-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-(2-hydroxy-3-morpholinopropyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo(3,2-c)azepin-4-ketone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07265921 2025-12-05

Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Recruiting

Advanced Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡